Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
2023年9月29日 - 3:46PM
Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”),
a clinical-stage biotechnology company focused on the development
of innovative cancer therapies, today announced the pricing of
its initial public offering of 2,500,000 American depositary shares
(“ADSs”), or 2,875,000 ADSs if the underwriters exercise their
over-allotment option in full, each representing three Class A
ordinary shares, at a public offering price of US$23.00 per ADS.
All of the ADSs were offered by Adlai Nortye. In addition, an
investor will acquire a total of 5,217,391 Class A ordinary shares
from Adlai Nortye in a private placement concurrent with the
closing of the public offering at the same per share purchase
price. Adlai Nortye expects to receive aggregate gross proceeds of
US$97.5 million, including US$57.5 million from the public offering
(before deducting underwriting discounts and commissions and
offering expenses, and not taking into account potential exercise
of the underwriters’ over-allotment option) and US$40.0 million
from the concurrent private placement. Assuming the over-allotment
option is exercised in full, the aggregate gross proceeds to be
received by Adlai Nortye may reach up to approximately US$106.1
million.
The ADSs are expected to begin trading on the
Nasdaq Global Market on September 29, 2023 under the ticker symbol
“ANL”. The offering is expected to close on October 3, 2023,
subject to the completion of customary closing conditions.
Cantor Fitzgerald & Co. is acting as sole
book-running manager for the public offering.
A registration statement relating to the
publicly offered securities has been filed with the U.S. Securities
and Exchange Commission ("SEC”) and became effective on September
28, 2023. The public offering is being made only by means of a
written prospectus. A copy of the final prospectus relating to the
public offering, when available, may be obtained from: Cantor
Fitzgerald & Co., Attention: Capital Markets, 110 East 59th
Street., 6th Floor, New York, New York 10022, or by email at
prospectus@cantor.com.
This press release shall not constitute an offer
to sell, or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Adlai NortyeAdlai Nortye
is a global clinical-stage biotechnology company focused on the
discovery and development of innovative cancer therapies for
patients across the spectrum of tumor types, with global R&D
centers established in New Jersey and Hangzhou. With a strategic
emphasis on oncology. The Company has identified and developed a
robust pipeline of six drug candidates.
Adlai Nortye has assembled a management team and
a scientific advisory board with industry leaders and influential
scientists, who provide international and strategic guidance to its
R&D, business development, and operational teams. In addition
to building its own R&D capabilities, the Company continues to
seek and secure partnerships with leading multi-national
pharmaceutical companies such as Eisai and Novartis, to fully
realize the potential of its pipeline programs. The Company strives
to become a global leader in the next wave of immuno-oncology
therapies employing a combination therapy strategy. Its ultimate
goal is to transform deadly cancer into a chronic and eventually
curable disease.
Forward-Looking and Cautionary
StatementsThis press release contains statements that
constitute “forward-looking statements,” including with respect to
the proposed initial public offering and the concurrent private
placement. No assurance can be given that the offering discussed
above will be completed on the terms described, or at all.
Forward-looking statements are subject to numerous conditions, many
of which are beyond the control of the Company, including those set
forth in the Risk Factors section of the Company’s registration
statement and prospectus for the Company’s offering filed with the
SEC. Copies are available on the SEC’s website, www.sec.gov. The
Company undertakes no obligation to update these statements for
revisions or changes after the date of this release, except as
required by law.
Contacts:Investor
Relations:Charles ZhouAmanda Kong
Adlai Nortye Ltd.ir@adlainortye.com
Adlai Nortye (NASDAQ:ANL)
過去 株価チャート
から 11 2024 まで 12 2024
Adlai Nortye (NASDAQ:ANL)
過去 株価チャート
から 12 2023 まで 12 2024